Profit With the Pros: March 18, 2025 ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Profit With the Pros: March 18, 2025 ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Profit With the Pros: March 11, 2025 ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Profit With the Pros: March 11, 2025 ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| 
Pharma Stock Tumbles After Disappointing Trial Data Pharmaceutical stocks are known for being volatile, and this week Incyte (INCY) showed investors why. The company’s phase three trial data for its latest skin disease treatment showed it was only effective for half of participants, setting the shares on track for their biggest single-day percentage loss since 2018. Below, let’s dig deeper into the stock’s reaction to the lackluster data, as well as its longer-term performance. Navigating Wall Street: Choose Your Own Adventure Wall Street is at a crossroads right now. Depending on who you talk to, this is either a long overdue correction or a chance to scoop up capitulated growth stocks on the cheap. The path forward is unclear, so we presented two roads for an investor. One is bracing for a recession and scrambling for ways to hedge and protect themselves. The other is buying the dip and reading sentiment shifts as an opportunity. Whichever path chosen, one thing is clear; options popularity continues to soar. Getting familiar with the various strategies and directional options should be the common thread among various stock market outlooks. Is It Time to Buy the Dip on Tech? Schaeffer’s Senior Quantitative Analyst is back again for his Indicator of the Week, this time zooming in on the tech sector. Volatility in the tech-heavy Nasdaq Composite (IXIC) over the past few weeks have brought an intriguing question to options traders: is now the time to buy the dip in tech? Be one of the first to see how the Nasdaq tends to perform after sitting deep in correction territory! Top Gold Stocks Ready to Surge as Gold Hits All-Time Highs (ad) Gold prices have climbed steadily for the past two years – soaring to a record-high of $2,700 at the end of 2024 – with no sign of slowing down. In fact, Goldman Sachs has predicted gold will reach $2,900/oz. here in early 2025 and both Citibank and Bank of America calling for $3,000 gold here in 2025. So how should you invest for maximum potential upside during these precarious times? Tariff Turmoil: Steel and Aluminum Stocks in Focus The latest U.S. tariffs on steel and aluminum are already shaking Wall Street, putting major metal producers Nucor Corp (NUE) and Alcoa Corp (AA) in the spotlight. President Donald Trump’s 25% tariffs on imported metals took effect Wednesday, triggering swift retaliation from the European Union (EU) and fueling market volatility. While Trump initially floated a 50% tariff on Canadian steel and aluminum, he pulled back after Ontario dropped its 25% surtax on U.S. electricity exports. How will these moves impact metal markets and traders? 
Schaeffer's Investment Research
5151 Pfeiffer Road, Cincinnati, OH45242
Unsubscribe |
|
No comments:
Post a Comment